Cargando…

The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses

BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more in...

Descripción completa

Detalles Bibliográficos
Autores principales: Goletti, Delia, Petrone, Linda, Manissero, Davide, Bertoletti, Antonio, Rao, Sonia, Ndunda, Nduku, Sette, Alessandro, Nikolayevskyy, Vladyslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272618/
https://www.ncbi.nlm.nih.gov/pubmed/34256141
http://dx.doi.org/10.1016/j.cmi.2021.07.005
_version_ 1783721252975804416
author Goletti, Delia
Petrone, Linda
Manissero, Davide
Bertoletti, Antonio
Rao, Sonia
Ndunda, Nduku
Sette, Alessandro
Nikolayevskyy, Vladyslav
author_facet Goletti, Delia
Petrone, Linda
Manissero, Davide
Bertoletti, Antonio
Rao, Sonia
Ndunda, Nduku
Sette, Alessandro
Nikolayevskyy, Vladyslav
author_sort Goletti, Delia
collection PubMed
description BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed. OBJECTIVES: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB). SOURCES: PubMed articles up to 16 April 2021. CONTENT: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4(+) and CD8(+) T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors. IMPLICATIONS: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest.
format Online
Article
Text
id pubmed-8272618
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-82726182021-07-20 The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses Goletti, Delia Petrone, Linda Manissero, Davide Bertoletti, Antonio Rao, Sonia Ndunda, Nduku Sette, Alessandro Nikolayevskyy, Vladyslav Clin Microbiol Infect Narrative Review BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed. OBJECTIVES: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB). SOURCES: PubMed articles up to 16 April 2021. CONTENT: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4(+) and CD8(+) T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors. IMPLICATIONS: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021-12 2021-07-10 /pmc/articles/PMC8272618/ /pubmed/34256141 http://dx.doi.org/10.1016/j.cmi.2021.07.005 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Narrative Review
Goletti, Delia
Petrone, Linda
Manissero, Davide
Bertoletti, Antonio
Rao, Sonia
Ndunda, Nduku
Sette, Alessandro
Nikolayevskyy, Vladyslav
The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
title The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
title_full The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
title_fullStr The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
title_full_unstemmed The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
title_short The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
title_sort potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific t-cell responses
topic Narrative Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272618/
https://www.ncbi.nlm.nih.gov/pubmed/34256141
http://dx.doi.org/10.1016/j.cmi.2021.07.005
work_keys_str_mv AT golettidelia thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT petronelinda thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT manisserodavide thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT bertolettiantonio thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT raosonia thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT ndundanduku thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT settealessandro thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT nikolayevskyyvladyslav thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT golettidelia potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT petronelinda potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT manisserodavide potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT bertolettiantonio potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT raosonia potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT ndundanduku potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT settealessandro potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses
AT nikolayevskyyvladyslav potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses